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Type 2 diabetes mellitus (T2DM) is a global pandemic, as evident from the global 
cartographic picture of diabetes by the International Diabetes Federation (http://www.
diabetesatlas.org/). Diabetes mellitus is a chronic, progressive, incompletely understood 
metabolic condition chiefly characterized by hyperglycemia. Impaired insulin secretion, 
resistance to tissue actions of insulin, or a combination of both are thought to be the 
commonest reasons contributing to the pathophysiology of T2DM, a spectrum of dis-
ease originally arising from tissue insulin resistance and gradually progressing to a state 
characterized by complete loss of secretory activity of the beta cells of the pancreas. 
T2DM is a major contributor to the very large rise in the rate of non-communicable dis-
eases affecting developed as well as developing nations. In this mini review, we endeavor 
to outline the current management principles, including the spectrum of medications 
that are currently used for pharmacologic management, for lowering the elevated blood 
glucose in T2DM.
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inTRODUCTiOn
Diabetes mellitus (DM) is a complex chronic illness associated with a state of high blood glucose 
level, or hyperglycemia, occurring from deficiencies in insulin secretion, action, or both. The chronic 
metabolic imbalance associated with this disease puts patients at high risk for long-term macro- and 
microvascular complications, which if not provided with high quality care, lead to frequent hospitali-
zation and complications, including elevated risk for cardiovascular diseases (CVDs) (1). The clinical 
diagnosis of diabetes is reliant on either one of the four plasma glucose (PG) criteria: elevated (i) fast-
ing plasma glucose (FPG) (>126 mg/dL), (ii) 2 h PG during a 75-g oral glucose tolerance test (OGTT) 
(>200 mg/dL), (iii) random PG (>200 mg/dL) with classic signs and symptoms of hyperglycemia, or 
(iv) hemoglobin A1C level >6.5%. Recent American Diabetes Association (ADA) guidelines have 
advocated that no one test may be preferred over another for diagnosis. The recommendation is to 
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test all adults beginning at age 45 years, regardless of body weight, 
and to test asymptomatic adults of any age who are overweight or 
obese, present with a diagnostic symptom, and have at least an 
additional risk factor for development of diabetes.
Furthermore, a condition called prediabetes or impaired 
fasting glucose (IFG), in which the fasting blood glucose is 
raised more than normal but does not reach the threshold to 
be considered diabetes (110–126  mg/dL), predisposes patients 
to diabetes, insulin resistance, and higher risk of cardiovascular 
(CV) and neurological pathologies (2, 3). Type 2 diabetes mel-
litus (T2DM) can co-occur with other medical conditions, such 
as gestational diabetes occurring during the second or third tri-
mester of pregnancy or pancreatic disease associated with cystic 
fibrosis. T2DM may also be iatrogenically induced, e.g., by use 
of glucocorticoids in the inpatient setting or use of highly active 
antiretroviral agents like protease inhibitors and nucleoside 
reverse transcription inhibitors in HIV-positive individuals (4). 
Chemical diabetes or impaired glucose tolerance (IGT) may also 
develop with the use of thiazide diuretics, atypical antipsychotic 
agents, and statins (5, 6).
Type 2 diabetes mellitus is a common and increasingly 
prevalent disease and is thus a major public health concern 
worldwide. The International Diabetes Federation estimates 
that there are approximately 387 million people diagnosed with 
diabetes across the globe (7). According to Centers for Disease 
Control and Prevention, in 2012, 29.1 million adults, or 9.3% 
of the population, were identified with diabetes in the United 
States (US). Also in the same year, 86 million people had predia-
betes condition and 15–30% of them developed into full-blown 
diabetes (8). In general, 1.4 million newly diagnosed cases in 
the US are being reported every year. If this trend continues, 
it is projected that in 2050 one in three Americans will have 
diabetes. Patients with diabetes have increased risk of serious 
health complications including myocardial infarction, stroke, 
kidney failure, vision loss, and premature death. Diabetes, with 
its associated side effects, remains the seventh leading cause of 
mortality in the US. The World Health Organization estimates 
that by 2030, mortality related to diabetes will double in number 
if not given deliberate attention (9). In addition, epidemiological 
studies report that diabetes causes more deaths in Americans 
every year compared to breast cancer and acquired immunodefi-
ciency syndrome (AIDS) combined (10). The increasing trend in 
the incidence and prevalence of diabetes is worrisome and poses 
a great burden on medical costs and in our current healthcare 
system.
The ADA has released a range of recommendations called 
Standards of Medical Care in Diabetes to improve diabetes out-
comes. The recommendations include cost-effective screening, 
diagnostic and therapeutic strategies to prevent, delay, or effec-
tively manage T2DM and its life-threatening complications (11). 
Per recommendations of ADA and other organizations, modern 
approaches to diabetes care should involve a multidisciplinary 
team of health professionals working in tandem with the patient 
and the family (2). The primary aim of these approaches is to 
obtain optimal glycemic control through dietary and lifestyle 
modifications and appropriate medications along with regular 
blood glucose level monitoring. The burden of diabetes can 
be potentially reduced if the standard of care is implemented 
as well as patients’ compliance and participation is clinically 
implemented.
The traditional presentations of T2DM occurring only in 
adults and type 1 diabetes mellitus (T1DM) only in children are 
not entirely correctly representative, as both diseases occur in 
both age groups. Occasionally, patients with T2DM may develop 
the morbid complication of diabetic ketoacidosis (DKA) (12). 
Children with T1DM typically present with polyuria and poly-
dipsia and approximately one-third of them present with DKA, 
which may also be the first presenting feature (12). The onset of 
T1DM may be variable in adults, and they may not present with 
the classic symptoms that are seen in children. The true diagnosis 
may become apparent with disease progression. The heterogene-
ity of the presentations should be kept in mind while caring for 
the patient with T2DM.
The scope of this review encompasses current clinical guide-
lines on the pharmacological management of T2DM.
CLiniCAL DiAGnOSiS OF TYPe 2 
DiABeTeS
Diabetes may be identified in low-risk individuals who have 
spontaneous glucose testing during routine primary clinical 
care, in individuals examined for diabetes risk assessment, and 
in frankly symptomatic patients. Early diagnosis of T2DM can be 
accomplished through blood tests that measure PG levels. FPG is 
the most common test to detect diabetes: a level of ≥126 mg/dL 
or 7.0 mmol/L confirmed by repeating the test on another clinic 
visit effectively diagnoses the disease. This test requires fasting 
for at least the previous 8 h and generates enhanced reliability 
when blood is drawn in the morning. Another criterion is the 2 h 
PG of ≥200 mg/dL or 11.1 mmol/L in a patient presenting with 
the traditional symptoms of diabetes such as polyuria, polydip-
sia, and/or unexplained weight loss. A positive 2-h OGTT will 
show a PG level of ≥200 mg/dL or 11.1 mmol/L after a glucose 
load containing 75 g of glucose solution in water. Two-hour PG 
OGTT is not commonly used in the clinic because, although it 
is more sensitive than FPG test, it is less convenient and more 
expensive for patients. Additionally, this test holds less relevance 
in routine follow-ups after confirmed diagnosis of diabetes is 
obtained.
In the past, the glycated hemoglobin (HbA1C) test was used 
mainly to monitor the adequacy of glycemic management and has 
strong predictive value for diabetes complications (13). HbA1C 
is a chronic marker of hyperglycemia and reflects patient’s blood 
glucose level over a period of 3–4 months, coinciding with the 
lifespan of the red blood cells (RBCs). However, in 2009 after 
its standardization, the International Expert Committee recom-
mended it to be used in diagnosing T2DM but not in T1DM and 
gestational diabetes (2). HbA1C level is reported in percentages, 
and a normal level is below 5.7%. The main advantage of the 
HbA1C test over other blood glucose tests is the convenience it 
offers to patients; it does not require fasting and can be done at 
any time of the day. However, this test is more expensive and may 
not be readily available in certain locations, which may limit its 
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usefulness (14, 15). HbA1C may be inaccurate in conditions such 
as anemia, hemolysis, and other hemoglobinopathies like sickle 
cell disease and hemoglobin (Hb) variants like HbC, HbE, and 
HbD, as well as elevated fetal hemoglobin. Thus, HbA1C assay 
in people of South Asian, Mediterranean, or African origin merit 
taking these issues into account (16). In conditions associated 
with increased RBC breakdown, such as in the advanced trimes-
ters of pregnancy, recent hemorrhage, intravascular hemolysis 
or transfusion or erythropoietin treatment, only blood glucose 
estimation should be used to diagnose diabetes. There are limited 
data supporting the use of A1C in diagnosing T2DM in children 
and adolescents. Although A1C is not routinely suggested for 
diagnosis of diabetes in children with cystic fibrosis or symptoms 
that portend development of acute onset of T1DM, the ADA 
recommends HbA1C for diagnosis of T2DM in children and 
adolescents.
In order to accurately diagnose diabetes and in the absence of 
frank hyperglycemia (PG > 200 mg/dL) or hyperglycemic crisis, 
it is useful to repeat the same diagnostic test for confirmation. 
In situations where there are two different tests with conflicting 
results, the test which is positive should be repeated and a diagno-
sis of diabetes is made after a confirmatory test has been done (2). 
For individuals whose test result/s returned negative for diabetes, 
repeat testing at 3-year intervals is suggested (17).
The ADA and American Association of Clinical 
Endocrinologists recommend screening for prediabetes begin-
ning at age 45 years or earlier for asymptomatic individuals with 
strong risk factors such as obesity (BMI ≥ 25 kg/m2), hyperten-
sion and family history (first degree relative with diabetes) (18). 
IFG level of 100–125 mg/dL (5.6–6.9 mmol/L), IGT with a 2-h 
OGTT PG level between 140 and 199 mg/dL (7.9–11.0 mmol/L), 
or an HbA1C of 5.7–6.4% indicates prediabetes. Patients with 
an HbA1C level of >6% are considered high risk of developing 
diabetes, and early detection is necessary to prevent adverse out-
comes. Patients diagnosed with prediabetes can be retested after 
a year; however, without proper intervention 70% of individuals 
diagnosed with prediabetes are most likely to progress to diabetes 
in 10 years or even less, depending on their risk factors (18). It 
is also important to note that prediabetes may be associated 
with obesity, dyslipidemia, and hypertension; therefore, lifestyle 
changes such as healthy diet, physical activity, and cessation of 
smoking, in addition to the introduction of pharmacological 
agents, are deemed important to stop or delay the timeline of 
development of diabetes.
CLiniCAL MAnAGeMenT OF TYPe 2 
DiABeTeS
Comprehensive care for a patient with diabetes requires an 
initial evaluation of the patient’s risk factors, the presence or 
absence of diabetes complications, and initial review of previ-
ous treatment/s (2). This will enable the healthcare providers to 
optimally manage patients with either prediabetes or diabetes. 
The cornerstones of diabetes management include lifestyle 
intervention along with pharmacological therapy and routine 
blood glucose monitoring.
Lifestyle Measures
Clinical trials have shown that lifestyle modifications are cost-
effective in preventing or delaying the onset of diabetes, with 
approximately 58% reduction in risk in 3 years (19). It is highly 
recommended by the ADA that patients with IGT, IFG or HbA1C 
level of 5.7–6.4% be counseled on lifestyle changes such as diet 
and exercise. On the other hand, for patients who are already 
diagnosed with diabetes, nutrition advice provided by a registered 
dietitian is recommended. A goal of moderate weight loss (≈7% 
of body weight) is an important component in the prevention and 
treatment of diabetes, as it can improve blood glucose levels, and 
can also positively impact blood pressure and cholesterol levels 
(19). Weight loss can be achieved through a healthy balanced diet, 
with control of total calories and free carbohydrates. However, 
for patients with diabetes adhering to a low carbohydrate diet, 
they should be informed on possible side effects such as hypo-
glycemia, headache and constipation (20). Other studies have 
suggested consumption of complex dietary fiber and whole grains 
to improve glycemic control (2, 21).
Studies show that exercise can improve glycemic control 
(lower HbA1C level by 0.66%), with or without significant 
decrease in body weight, and improve the total well-being of 
patients (22). It is considered an integral part in the prevention 
and management of both prediabetes and diabetes. According 
to the U.S. Department of Health and Human Services, adults 
≥18  years of age should do a minimum of 150  min/week of 
moderate intensity exercise (e.g., walking at a 15- to 20-min mile 
pace) or 75 min/week of vigorous physical activity (e.g., running, 
aerobics) spread over at least 3 days/week with no more than two 
consecutive days without exercise to achieve maximum benefits 
(2, 18). For patients ≤18 years old, 60 min of physical activity 
every day is adequate.
Other lifestyle measures that need to be considered in the 
treatment plan for patients with diabetes are moderate alcohol 
consumption (≤1 drink for women, ≤2 drinks/men) and reduc-
tion in sodium intake especially in patients with comorbidities 
such as hypertension, habitual tobacco use, and lacking immuni-
zations (influenza, diphtheria, pertussis, tetanus, pneumococcal, 
and hepatitis B). Consumption of alcohol, especially in a fasted 
state, can precipitate life-threatening hypoglycemia and coma 
and should be explicitly counseled to patients during their visits 
(23). Moreover, patient education, counseling, and psychosocial 
support are very important to successfully combat the deleterious 
effects of diabetes.
Pharmacologic Management
An “ominous octet” that leads to hyperglycemia, which occur 
in isolation or in combination, has been proposed for eight 
pathophysiological mechanisms underlying T2DM (24). These 
include (i) reduced insulin secretion from pancreatic β-cells, (ii) 
elevated glucagon secretion from pancreatic α cells, (iii) increased 
production of glucose in liver, (iv) neurotransmitter dysfunction 
and insulin resistance in the brain, (v) enhanced lipolysis, (vi) 
increased renal glucose reabsorption, (vii) reduced incretin effect 
in the small intestine, and (viii) impaired or diminished glucose 
uptake in peripheral tissues such as skeletal muscle, liver, and 
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adipose tissue. Currently available glucose-lowering therapies 
target one or more of these key pathways.
Good glycemic control remains the main foundation of 
managing T2DM. Such approaches play a vital role in preventing 
or delaying the onset and progression of diabetic complications. 
It is important that a patient-centered approach should be used 
to guide the choice of pharmacological agents. The factors to be 
considered include efficacy, cost, potential side effects, weight 
gain, comorbidities, hypoglycemia risk, and patient preferences. 
Pharmacological treatment of T2DM should be initiated when 
glycemic control is not achieved or if HbA1C rises to 6.5% after 
2–3 months of lifestyle intervention. Not delaying treatment and 
motivating patients to initiate pharmacotherapy can considerably 
prevent the risk of the irreversible microvascular complications 
such as retinopathy and glomerular damage (25). Monotherapy 
with an oral medication should be started concomitantly with 
intensive lifestyle management.
The major classes of oral antidiabetic medications include 
biguanides, sulfonylureas, meglitinide, thiazolidinedione (TZD), 
dipeptidyl peptidase 4 (DPP-4) inhibitors, sodium-glucose 
cotransporter (SGLT2) inhibitors, and α-glucosidase inhibitors. 
If the HbA1C level rises to 7.5% while on medication or if the 
initial HbA1C is ≥9%, combination therapy with two oral agents, 
or with insulin, may be considered (2, 26). Though these medica-
tions may be used in all patients irrespective of their body weight, 
some medications like liraglutide may have distinct advantages 
in obese patients in comparison to lean diabetics (see below). 
A schematic of currently approved medications for T2DM is 
summarized in Table 1. A flowchart for guiding clinical decision 
making is presented in Figure 1.
Biguanide
The discovery of biguanide and its derivatives for the manage-
ment of diabetes started in the middle ages. Galega officinalis, a 
herbaceous plant, was found to contain guanidine, galegine, and 
biguanide, which decreased blood glucose levels (31). Metformin 
is a biguanide that is the main first-line oral drug of choice in the 
management of T2DM across all age groups. Metformin activates 
adenosine monophosphate-activated protein kinase in the liver, 
causing hepatic uptake of glucose and inhibiting gluconeogenesis 
through complex effects on the mitochondrial enzymes (31). 
Metformin is highly tolerated and has only mild side effects, low 
risk of hypoglycemia and low chances of weight gain. Metformin 
is shown to delay the progression of T2DM, reduce the risk of 
complications, and reduce mortality rates in patients by decreas-
ing hepatic glucose synthesis (gluconeogenesis) and sensitizing 
peripheral tissues to insulin (31). Furthermore, it improves 
insulin sensitivity by activating insulin receptor expression and 
enhancing tyrosine kinase activity. Recent evidence also suggest 
that metformin lowers plasma lipid levels through a peroxisome 
proliferator-activated receptor (PPAR)-α pathway, which pre-
vents CVDs (31). Reduction of food intake possibly occurs by 
glucagon-like peptide-1 (GLP-1)-mediated incretin-like actions. 
Metformin may thus induce modest weight loss in overweight 
and obese individuals at risk for diabetes.
Once ingested, metformin (with a half-life of approximately 
5  h) is absorbed by organic cation transporters and remains 
unmetabolized in the body and is widely distributed into differ-
ent tissues such as intestine, liver, and kidney. The primary route 
of elimination is via kidney. Metformin is contraindicated in 
patients with advanced stages of renal insufficiency, indicated by 
a glomerular filtration rate (GFR) <30 mL/min/1.73 m2 (32). If 
metformin is used when GFR is significantly diminished, the dose 
should be reduced and patients should be advised to discontinue 
the medication if nausea, vomiting, and dehydration arises from 
any other cause (to prevent ketoacidosis). It is important to assess 
renal function prior to starting this medication.
Metformin has an excellent safety profile, though may cause 
gastrointestinal disturbances including diarrhea, nausea, and 
dyspepsia in almost 30% of subjects after initiation. Introduction 
of metformin at low doses often improve tolerance. Extended 
release preparations seldom cause any gastrointestinal issues. Very 
rarely, metformin may cause lactic acidosis, mainly in subjects 
with severe renal insufficiency. Another potential problem arising 
from the use of metformin is the reduction in the drug’s efficiency 
as diabetes progresses. Metformin is highly efficient when there 
is enough insulin production; however, when diabetes reaches 
the state of failure of β-cells and resulting in a type 1 phenotype, 
metformin loses its efficacy.
Metformin can cause vitamin B12 and folic acid deficiency 
(33). This needs to be monitored, especially in elderly patients. 
Though very rare, in patients with metformin intolerance or 
contraindications, an initial drug from other oral classes may 
be used. Although trials have compared dual therapy with 
metformin alone, few directly compare drugs as add-on therapy. 
A comparative effectiveness meta-analysis suggests that overall 
each new class of non-insulin medications introduced in addition 
to the initial therapy lowers A1C around 0.9–1.1%. An ongoing 
Glycemia Reduction Approaches in Diabetes: A Comparative 
Effectiveness Study (GRADE) has compared the effect of four 
major drug classes (sulfonylurea, DPP-4 inhibitor, GLP-1 analog, 
and basal insulin) over 4 years on glycemic control and other psy-
chosocial, medical, and health economic outcomes (34). Though 
it will be a welcome development for introduction of oral agents 
for metformin for gestational diabetes, current FDA regulations 
do not support it.
Incretin Mimetics
Incretin effect is the difference in insulin secretory response 
from an oral glucose load in comparison to glucose administered 
intravenously. The incretin effect is responsible for 50–70% of 
total insulin secretion after oral glucose intake (35). The two 
naturally occurring incretin hormones that play important roles 
in the maintenance of glycemic control: glucose-dependent 
insulinotropic polypeptide (GIP, or incretin) and glucagon-like 
peptide (GLP-1); these peptides have a short half-life, as these 
are rapidly hydrolyzed by DPP-4 inhibitors within 1½  min. In 
patients with T2DM, the incretin effect is reduced or absent. In 
particular, the insulinotropic action of GIP is lost in patients with 
T2DM. Incretins decrease gastric emptying and causes weight 
loss. Because of impact on weight loss, these medications may 
find increasing use in diabesity.
Targeting the incretin system has become an important 
therapeutic approach for treating T2DM. These two drug classes 
TABLe 1 | Pharmacological agents for glycemic control.
Class of 
antidiabetic 
medication (route 
of administration)
Representative 
agents
Mechanism of action T1/2 and 
metabolism
HbA1C 
reduction 
(%)
Risk of 
hypoglycemia
effect 
on body 
weight
Metabolic 
alterations
Cardiovascular 
(Cv) benefit and 
risk
Other adverse effects/
additional comments
Biguanide (o) Metformin Insulin sensitizer
Numerous effects on 
inhibition of hepatic 
glucose production
5 h; unmetabolized, 
renal excretion
1–2 None Mild 
weight 
loss 
due to 
anorectic 
effect
Lactic acidosis 
(very rare)
May cause 
nausea/vomiting 
or diarrhea after 
introduction, 
which may result 
in electrolyte or 
pH alterations
Reduce MI by 39% 
and coronary deaths 
by 50% (UKPDS)
Vitamin B12 deficiency, which 
may cause anemia and 
neuropathy (risk in elderly)
Very safe drug, but stop 
metformin if creatinine 
>1.5 mg/dL in males and 
>1.4 mg/dL in females
Dipeptidyl peptidase 
4 (DPP-IV)  
inhibitor (o)
Sitagliptin Inhibition of degradation 
of GLP
Excreted by kidneys 
(except linagliptin) 
(needs dose reduction 
in renal failure)
0.5–0.8 Low Long-term trials 
to assess CV 
risk; decreases 
postprandial lipemia, 
however, may cause 
CHF by degradation 
of BNP
Pancreatitis
Saxagliptin Upper RTI infection
Vidagliptin
Linagliptin
Alogliptin
Sodium-glucose 
cotransporter 
(SGLT2) inhibitor (o)
Canagliflozin Glucosuria due to 
blocking (90%) of 
glucose reabsorption 
in renal PCT; insulin-
independent mechanism 
of action
Low Positive CV effect 
due to reduction 
of sodium and uric 
acid absorption and 
reduction of BP
Ketoacidosis (rare)
Genital mycosis
May increase LDLc
Bone fractures
Dapagliflozin
Empagliflozin
Insulin (p) Short-acting
Regular (R) (Humulin R, 
Novolin R)
Intermediate
NPH (N)
Long-acting
Insulin glargine (Lantus)
Insulin detemir 
(Levemir)
Insulin degludec 
(Tresiba)
Rapid-acting
Humalog (Lispro)
Activation of insulin 
receptors and 
downstream signaling in 
multiple sensitive tissues
30 min-1 r (onset of 
action)
Peak 2–5 h
Duration of action 8 h
1.5–4 h (onset of 
action)
Peak 4–12 h
Duration of action 24 h
0.8–4 h (onset of 
action)
Peak minimal
Duration of action 24 h
10–30 min (onset of 
action)
1–2.5 Prominent Weight 
gain
HF if used in 
combination with 
thiazolidinediones 
(TZD)
Lipoatrophy and 
lipohypertrophy at sites of 
injection
Allergy to injection 
components
Levemir Food and Drug 
Administration -approved for 
gestational diabetes mellitus
(Continued)
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Class of 
antidiabetic 
medication (route 
of administration)
Representative 
agents
Mechanism of action T1/2 and 
metabolism
HbA1C 
reduction 
(%)
Risk of 
hypoglycemia
effect 
on body 
weight
Metabolic 
alterations
Cardiovascular 
(Cv) benefit and 
risk
Other adverse effects/
additional comments
Novolog (Aspart)
Glulisine (Apidra)
Pre-mixed
75% insulin lispro 
protamine/25% insulin 
lispro (Humalog Mix 
75/25)
50% insulin lispro 
protamine/50% insulin 
lispro (Humalog Mix 
50/50)
70% insulin lispro 
protamine/30% insulin 
aspart (Novolog 70/30)
70% NPH insulin/30% 
regular
Peak 30 min–3 h
Duration of action 
3–5 h
5–15 min (onset of 
action)
Peak dual
Duration of action 
10–16 h
30–60 min (onset of 
action)
Peak dual
Duration of action 
10–16 h
GLP-1 agonists (p) Liraglutide
Exenatide
Dulaglutide
Activate GLP1 receptor
Increased insulin 
secretion, decreased 
glucagon, delayed gastric 
emptying, increased 
satiety
24 h 0.5–1.5 No [risk if used 
in combination 
with 
sulfonylureas 
(SU)]
Weight 
loss
Reduce CV risk Nausea, vomiting, 
pancreatitis, C cell tumor of 
thyroid (contraindicated in 
MEN type 2)
4–6 h (short acting)
7 days (long acting, 
extended release)
7 days
SU (o) Glimepiride Insulin secretion 1–2 Prominent 
(severe in renal 
failure)
Weight 
gain
Increased 
cardiovascular 
disease risk, 
mainly due to 
hypoglycemia
Use beta-blockers with 
cautionGlipizide
Glyburide
TZD (o) Rosiglitazone True insulin sensitizer 0.5–1.4 Weight 
gain
Cardiac failure, 
pedal edema
Bladder cancer; fractures
Pioglitazone
O, oral; p, parenteral; iv, intravenous; sc, subcutaneous.
TABLe 1 | Continued
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FiGURe 1 | Flow chart depicting an algorithm for use of drug regimen in treating diabetes mellitus Several concepts presented here are adapted 
from American Diabetes Association/european Association for the Study of Diabetes (27–30). Medications in green, causes weight loss; in red, causes 
weight gain.
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include GLP-1 receptor agonists and DPP-4 inhibitors. Clinical 
data have revealed that these therapies improve glycemic control 
while reducing body weight (specifically, GLP-1 receptor ago-
nists) and systolic blood pressure in patients with T2DM (36). 
Furthermore, hypoglycemia is low (except when used in combi-
nation with a sulfonylurea) because of their glucose-dependent 
mechanism of action.
GLP-1 Receptor Agonists
The currently GLP-1 receptor agonists available are exenatide and 
liraglutide. These drugs exhibit increased resistance to enzymatic 
degradation by DPP4. In young patients with recent diagnosis 
of T2DM, central obesity, and abnormal metabolic profile, one 
should consider treatment with GLP-1 analogs that would have 
a beneficial effect on weight loss and improve the metabolic 
dysfunction. GLP-1 analogs are contraindicated in renal failure.
Exenatide. Exenatide, an exendin-4 mimetic with 53% sequence 
homology to native GLP-1, is currently approved for T2DM treat-
ment as a single drug in the US and in combination with met-
formin ± sulfonylurea. Because of its half-life of 2.4 h, exenatide 
is advised for twice-daily dosing. Treatment with 10 µg exenatide, 
as an add-on to metformin, resulted in significant weight loss 
(−2.8 kg) in comparison to patients previously treated with met-
formin alone. Exenatide is generally well tolerated, with mild-to-
moderate gastrointestinal effects being the most common adverse 
effect.
Liraglutide. Liraglutide is a GLP-1 analog that shares 97% 
sequence identity to native GLP-1. Liraglutide has a long dura-
tion of action (24  h). Liraglutide causes 1.5% decrease in A1C 
in individuals with type 2 diabetes, when used as monotherapy 
or in combination with one or more selected oral antidiabetic 
drugs. Liraglutide decreases body weight; the greatest weight 
loss resulted from treatment with liraglutide in combination 
with combined metformin/sulfonylurea (−3.24  kg with 1.8  mg 
liraglutide). Liraglutide also diminishes systolic pressure (mean 
decrease −2.1 to −6.7 mmHg) (37). Liraglutide is well tolerated, 
with only nausea and minor hypoglycemia (risk increased with 
use of sulfonylureas).
Serum antibody formation was very low in patients treated 
with once-weekly GLP-1 receptor agonists. The formation of 
these antibodies did not decrease efficacy of their actions on 
blood glucose lowering.
DPP-4 Inhibitors
Dipeptidyl peptidase 4 inhibitors include sitagliptin, saxaglip-
tin, vidagliptin, linagliptin, and alogliptin. These medications 
may be used as single therapy, or in addition with metformin, 
sulfonylurea, or TZD. This treatment is similar to the other oral 
antidiabetic drugs. The gliptins have not been reported to cause 
higher incidence of hypoglycemic events compared with controls.
Dipeptidyl peptidase 4 inhibitors impact postprandial lipid 
levels. Treatment with vidagliptin for 4  weeks decreases post-
prandial plasma triglyceride and apolipoprotein B-48-containing 
triglyceride-rich lipoprotein particle metabolism after a fat-rich 
meal in T2DM patients who have previously not been exposed 
to these medications. In diabetic patients with coronary heart 
disease, it was demonstrated that treatment with sitagliptin 
improved cardiac function and coronary artery perfusion.
The three most commonly reported adverse reactions in clini-
cal trials with gliptins were nasopharyngitis, upper respiratory 
tract infection, and headache. Acute pancreatitis was reported in 
a fraction of subjects taking sitagliptin or metformin and sitag-
liptin. An increased incidence of hypoglycemia was observed in 
the sulfonylurea treatment group.
In the elderly, DPP-4 inhibitors lower blood glucose but have 
minimal effect on caloric intake and therefore less catabolic 
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effect on muscle and total body protein mass. In decreased doses, 
DPP-4 inhibitors are considered safe in patients with moderate 
to severe renal failure.
SGLT2 Inhibitors
Sodium-glucose cotransporter inhibitors are new classes of 
glucosuric agents: canagliflozin, dapagliflozin, and empagliflozin. 
SGLT2 inhibitors provide insulin-independent glucose lowering 
by blocking glucose reabsorption in the proximal renal tubule by 
inhibiting SGLT2 (38).
Because of glucose-independent mechanism of action, these 
drugs may be effective in advanced stages of T2DM when pan-
creatic β-cell reserves are permanently lost. These drugs provide 
modest weight loss and blood pressure reduction.
Urinary tract infections leading to urosepsis and pyelonephri-
tis, as well as genital mycosis, may occur with SGLT2 inhibitors. 
SGLT2 inhibitors may rarely cause ketoacidosis. Patients should 
stop taking their SGLT2 inhibitor and seek medical attention 
immediately if they have symptoms of ketoacidosis (frank nau-
sea or vomiting, or even non-specific features like tiredness or 
abdominal discomfort).
Insulin
If non-insulin monotherapy like metformin at the maximum 
tolerated dose does not achieve or maintain the A1C target over 
3 months, then a second oral agent may be added to the regimen, 
a GLP-1 receptor agonist, or basal insulin. Insulin therapy (with 
or without additional agents) should be introduced in patients 
with newly identified T2DM and frankly symptomatic (catabolic 
features like weight loss, ketosis or features of hyperglycemia 
including polyuria/polydipsia) and/or severely elevated blood 
glucose levels [≥300–350  mg/dL (16.7–19.4  mmol/L)] or A1C 
[≥10–12%] (11).
The clinical picture of T2DM and its therapies should be 
regularly and objectively elaborated to patients. Many subjects 
with T2DM shall require insulin therapy sometime during the 
course of the disease. For patients with T2DM with inadequate 
target glycemic goals, insulin therapy should not be postponed. 
Providers should advocate insulin as a therapy in a complete non-
judgmental, empathetic, and non-punitive approach to ensure 
superior quality of adherence. Self-monitoring of blood glucose 
(SMBG) (discussed below) contributes to significant improve-
ment of glycemic control in patients with T2DM initiating 
insulin. Close and frequent monitoring of the patient is needed 
for any dose titration to achieve target glycemic goals, as well as 
to prevent hypoglycemia.
Basal insulin is the initial insulin regimen, beginning at 10 U or 
0.1–0.2 U/kg, depending on the hyperglycemia severity (titrating 
by 2–3 U every 4–7 days till glycemic goal is reached). Use of basal 
insulin greater than 0.5 U/kg indicates the need for use of an addi-
tional agent. Basal insulin is usually added to oral metformin and 
possibly one additional non-insulin agent like DPP-4 or SGLT-2 
inhibitor. NPH (neutral protamine Hagedorn) insulin carries 
low risk of hypoglycemia in individuals without any significant 
past history, and is low cost. Newer, longer acting, basal insulin 
analogs have superior pharmacodynamic profiles, delayed onset 
and longer duration of action but low risk of hypoglycemia, albeit 
at higher costs. Concentrated basal insulin preparations such as 
U-500 regular is five times more potent per volume of insulin 
(i.e., 0.01 mL ~5 U of U-100 regular) than U-100 regular. U-300 
glargine and U-200 degludec are other potent, ultra-long acting 
preparations.
If basal insulin contributes to acceptable fasting blood glucose, 
but A1C persistently remains above target, mealtime insulin may 
be added. Rapid-acting insulin analog (lispro, aspart, or glulisine) 
may be used and administered just before meals. The glucose 
levels should be monitored before meals and after the injections. 
Another approach to control the periprandial glucose excursions 
may be to add twice-daily premixed (or biphasic) insulin analogs 
(70/30 aspart mix, 75/25 or 50/50 lispro mix). The total present 
insulin dose may be computed and then one-half of this amount 
may be administered as basal and the other half during mealtime, 
the latter split equally between three meals. Regular human insu-
lin and human NPH–Regular premixed formulations (70/30) 
are less expensive alternatives to rapid-acting insulin analogs 
and premixed insulin analogs, respectively, but their unpredict-
able pharmacodynamic profiles make them inadequate to cover 
postprandial glucose changes.
Sometime, bolus insulin needs to be administered in addi-
tion to basal insulin. Rapid-acting analogs are used as bolus 
formulations due to their prompt onset of action. Insulin pump 
(continuous subcutaneous insulin infusion) may be used instead 
to avoid multiple injections. Often, patients and physicians are 
reluctant to intensify therapy due to the fear of hypoglycemia, 
regimen complexity, and increased multiple daily injections. 
There is a need for a flexible, alternative intensification option 
taking into account individual patient considerations to achieve 
or maintain individual glycemic targets. An ideal insulin regi-
men should mimic physiological insulin release while providing 
optimal glycemic control with low risk of hypoglycemia, weight 
gain, and fewer daily injections.
Inhaled insulin (Technosphere insulin-inhalation system, 
Afrezza) is now available for prandial use. However, the dosing 
range is limited. Use of inhaled insulin requires pulmonary func-
tion testing prior to and after starting therapy. It is contraindicated 
in subjects with asthma or other lung diseases.
During insulin therapy, sulfonylureas, DPP-4 inhibitors, and 
GLP-1 receptor agonists are stopped once more complex insulin 
regimens beyond basal insulin are used. In patients with inad-
equate blood glucose control, especially if requiring escalating 
insulin doses, TZDs (usually pioglitazone) or SGLT2 inhibitors 
may be added as adjunctive therapy to insulin.
Insulin injections can cause weight gain or loss. Insulin drives 
potassium into the cell and can cause hypokalemia. Components 
of the insulin preparation have the potential to cause allergy. 
Insulin injections, along with the use of other drugs like TZDs, 
can precipitate cardiac failure.
Stressful events like illness, surgery, and trauma can impede 
glycemic control and may lead to development of DKA or non-
ketotic hyperosmolar state, life-threatening conditions, which 
merits immediate medical attention. Any condition that deterio-
rates glycemic control necessitates more frequent monitoring of 
blood glucose in an inpatient setting; ketosis-prone patients also 
require urine or blood ketone monitoring. If accompanied by 
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ketosis, vomiting, or altered mental status, marked hyperglycemia 
requires hospital admission. The patient treated with non-insulin 
therapies or medical nutrition therapy alone may require insulin. 
Patient must be aggressively hydrated and infections should be 
controlled.
Without adequate treatment, prolonged hyperglycemia can 
cause glucose toxicity that can progressively impair insulin 
secretion. Initiation of insulin therapy is critical to reverse the 
toxic effect of high blood glucose levels on the pancreas. Once 
persistent glycemic control is achieved, insulin can be tapered 
off and replaced with oral medications. At some point in the 
management of T2DM, β-cell reserves are exhausted, with 
phenotypic reversal to a T1DM kind of pathophysiological situa-
tion. Meticulous follow-up may identify such states and then the 
need for continued reliance on insulin therapy may be carefully 
explained to the patients.
Weight gain can raise a barrier to the use of insulin in 
T2DM. In the United Kingdom Prospective Diabetes Study 
(UKPDS) study, patients gained 6 kg with insulin therapy, when 
compared with 1.7–2.6 kg weight gain with sulfonylureas (39). 
More recently, the combination of GLP-1 receptor agonists and 
insulin has been useful in tackling the weight gain associated 
with insulin and circumventing the need for high doses in the 
presence of significant insulin resistance. Lipoatrophy with 
insulin injections is not seen now; however, lipohypertrophy 
due to failure to change the subcutaneous injection sites is still 
a common cause of poor insulin absorption and suboptimal 
glycemic control.
In the Action to Control Cardiovascular Risk in Diabetes 
trial, aggressive treatment of T2DM patients with higher CV risk 
was associated with higher all-cause and CV mortality. Post hoc 
analyses could not find correlation with faster rates of reduction 
of glucose, hypoglycemia, or specific drugs as the causes underly-
ing this finding. Exposure to injected insulin was hypothesized 
to increase CV mortality. However, after adjustment for baseline 
covariates, no significant association of insulin dose with CV 
death remained (40). Older patients with cognitive dysfunction 
may not benefit from intensive therapy. Furthermore, hypogly-
cemia in the elderly may cause cardiac ischemia, arrhythmia, 
myocardial infarction, and sudden death (41).
Sulfonylureas
Sulfonylureas lower blood glucose level by increasing insulin 
secretion in the pancreas by blocking the KATP channels. They 
also limit gluconeogenesis in the liver. Sulfonylureas decrease 
breakdown of lipids to fatty acids and reduce clearance of insulin 
in the liver (42). Sulfonylureas are currently prescribed as second-
line or add-on treatment options for management of T2DM. 
They are divided into two groups: first-generation agents, which 
includes chlorpropamide, tolazamide, and tolbutamide, and 
second-generation agents, which includes glipizide, glimepiride, 
and glyburide. The first-generation sulfonylureas are known to 
have longer half-lives, higher risk of hypoglycemia, and slower 
onset of action, as compared to second-generation sulfonylureas. 
Currently, in clinical practice, second-generation sulfonylureas 
are prescribed and more preferred over first-generation agents 
because they are proven to be more potent (given to patients at 
lower doses with less frequency), with the safest profile being that 
of glimepiride.
Hypoglycemia is the major side effect of all sulfonylureas, 
while minor side effects such as headache, dizziness, nausea, 
hypersensitivity reactions, and weight gain are also common. 
Sulfonylureas are contraindicated in patients with hepatic 
and renal diseases and are also contraindicated in pregnant 
patients due to the possible prolonged hypoglycemic effect 
to infants. Drugs that can prolong the effect of sulfonylureas 
such as aspirin, allopurinol, sulfonamides, and fibrates must be 
used with caution to avoid hypoglycemia. Moreover, other oral 
antidiabetic medications or insulin can be used in combination 
with sulfonylurea and can substantially increase the risk of 
hypoglycemia.
Patients on beta-adrenergic antagonists for the management of 
hypertension can have hypoglycemia unawareness. Sulfonylureas 
should be used with caution in subjects receiving beta blockers.
Meglitinide
Meglitinides (repaglinide and nateglinide) are non-sulfonylurea 
secretagogues, which was approved as treatment for T2DM in 
1997. Meglitinide shares the same mechanism as that of sulfo-
nylureas; it also binds to the sulfonylurea receptor in β-cells of 
the pancreas. However, the binding of meglitinide to the receptor 
is weaker than sulfonylurea, and thus considered short-acting 
insulin secretagogues, which gives flexibility in its administra-
tion. Also, a higher blood sugar level is needed before it can 
stimulate β-cells’ insulin secretion, making it less effective than 
sulfonylurea. Rapid-acting secretagogues (meglitinides) may 
be used in lieu of sulfonylureas in patients with irregular meal 
schedules or those who develop late postprandial hypoglycemia 
while using a sulfonylurea.
Thiazolidinedione
Like biguanides, TZDs improve insulin action. Rosiglitazone 
and pioglitazone are representative agents. TZDs are agonists of 
PPAR and facilitate increased glucose uptake in numerous tis-
sues including adipose, muscle, and liver. Mechanisms of action 
include diminution of free fatty acid accumulation, reduction in 
inflammatory cytokines, rising adiponectin levels, and preserva-
tion of β-cell integrity and function, all leading to improvement of 
insulin resistance and β-cell exhaustion. However, there are high 
concerns of risks overcoming the benefits. Namely, combined 
insulin-TZD therapy causes heart failure. Thus, TZDs are not 
preferred as first-line or even step-up therapy.
Other Glucose-Lowering Pharmacologic Agents
Pramlintide, an amylin analog, is an agent that delays gastric 
emptying, blunts pancreatic secretion of glucagon, and enhances 
satiety. It is a Food and Drug Administration (FDA)-approved 
therapy for use in adults with T1DM. Pramlintide induces weight 
loss and lowers insulin dose. Concurrent reduction of prandial 
insulin dosing is required to reduce the risk of severe hypogly-
cemia. Other medications that may lower blood sugar include 
bromocriptine, alpha-glucosidase inhibitors like voglibose and 
acarbose, and bile acid sequestrants like colesevelam. It may be 
noted that metformin sequesters bile acids in intestinal lumen and 
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thus has a lipid-lowering effect, also the same mechanism may 
contribute to gas production and gastrointestinal disturbances.
Pharmacologic Management of Diabetes 
Complications
Important components of the Standards of Medical Care in 
Diabetes involves taking care of complications of diabetes and 
comorbidities including hypertension, atherosclerotic cardio-
vascular disease (ASCVD), dyslipidemia, hypercoagulopathy, 
endothelial cell dysfunction, nephropathy, and retinopathy. 
CVD is the most important cause of morbidity and mortality in 
patients with diabetes. The currently recommended goal blood 
pressure is ≤140/80 for patients with diabetes and hyperten-
sion. Angiotensin-converting enzyme inhibitors or angiotensin 
receptor blockers are the preferred antihypertensive medication 
(2). Optimal blood pressure and blood glucose control can 
effectively delay the progression of nephropathy and retin-
opathy in these patients. Patients with existing CVD should 
be continuously managed with aspirin, including providing 
primary prevention in subjects less than 50 years old. Patients 
with diabetes are also recommended to undergo annual lipid 
profile measurement, and those diagnosed with hyperlipidemia 
should be treated with statins with a low-density lipoprotein 
goal of <70  mg/dL (2). Moreover, it should be noted that an 
important aspect in the success of pharmacotherapy is patient’s 
adherence and compliance to medications; therefore, close 
and regular patient follow-up, monitoring, and education are 
necessary.
Glucose Monitoring
Self-monitoring of blood glucose and HbA1C are integral com-
ponents of the standards of care in diabetes. They are designed to 
assess the effectiveness of a treatment plan and provide guidance 
in selecting appropriate medications and dosage/s (2). SMBG 
allows patients to assess their own response to medication, 
minimize the risk of hypoglycemia, and determine whether 
they are achieving glycemic control. Optimal glycemic control is 
achieved when FPG is 70–130 mg/dL, 2 h post prandial <180 mg/
dL, and bedtime glucose is 90–150 mg/dL. However, testing six 
to eight times daily may burden patients and may result in non-
compliance. Therefore, it is recommended to ensure that patients 
are properly instructed and are given regular evaluation and 
follow-up.
Self-monitoring of blood glucose is essential in patients with 
diabetes who are on intense insulin regimen (three to four injec-
tions of basal and prandial or insulin pump). It monitors and 
prevents hyperglycemia and possible side effect of hypoglycemia. 
Blood glucose level is usually checked prior to meals, prior to 
exercise, prior to driving, and at bedtime. Evidence is insufficient 
to prescribe SMBG for patients not receiving an intensive insulin 
regimen (26).
According to the current guideline, HbA1C level should be 
assessed regularly in all patients with diabetes. The frequency of 
HbA1C testing is flexible and depends primarily on the response 
of patients to therapy and the physician’s judgment. HbA1C 
testing is performed at least every 6 months for patients who are 
meeting treatment goals; for patients who are far from their gly-
cemic goals, HbA1C testing may be performed more frequently.
SUMMARY/COnCLUSiOn
Type 2 diabetes mellitus is one of the leading causes of renal fail-
ure, ASCVD, non-traumatic lower limb amputation, blindness, 
and death worldwide. It is a serious chronic medical condition 
that requires a multidisciplinary team approach, consisting of 
healthcare professionals, dietitians, patient educators, patients, 
and their families. Lifestyle intervention designed to manage 
body weight and treat obesity, as well as patient education, are 
essential for all patients with diabetes. Treatment options may 
be individualized and medication(s) chosen based on a patient’s 
risk factors, current HbA1C level, medication efficacy, ease of use, 
patient’s financial situation/insurance/costs, and risk of side effects 
such as hypoglycemia and weight gain. Effectiveness of therapy 
must be evaluated as frequent as possible using diagnostic blood 
tests (HbA1C), as well as monitoring for development of diabetic 
complications (e.g., retinopathy, nephropathy, neuropathy). 
Furthermore, aggressive efforts from physicians and motivating 
patients for compliance are the two important aspects of the 
prevention and management of diabetes. Sociocultural issues 
should be carefully considered. For example, during religious 
fasting (e.g., during the holy month of Ramadan), the use of phar-
macologic agents that induce hypoglycemia should be used with 
care and insulin doses (for example, premix formulations) should 
be appropriately titrated and the patient should be educated for 
blood glucose monitoring and breaking of fast as needed (43).
By the year 2030, >70% of people with T2DM shall reside in 
developing countries (44). Primary prevention of T2DM should 
be an urgent public health policy. The disease predominantly 
affects working-age people and therefore has a counterproduc-
tive economic impact, compounded by the frequent occurrence 
and interaction of T2DM with infectious diseases (such as AIDS 
and tuberculosis) (45). Evidence from landmark T2DM preven-
tion trials indicates that lifestyle modification is more effective, 
cheaper, and safer than medication and provides sustained 
benefits. Lifestyle modification may be promising approach to 
T2DM prevention in developing countries. This will be useful 
for many ethnic groups in the U.S. as well, such as South Asian, 
Latino, Pima Indians, and African-American populations, which 
may face socioeconomic challenges similar to what is seen in 
developing countries. Cost-contained strategies to identify at-
risk individuals, followed by the implementation of group-based, 
inexpensive lifestyle interventions (“comfortably uncomfortable” 
life, as lived by people in blue zones), seem to be the best options 
for resource-constrained settings. T2DM pathophysiology is 
increasingly understood as a mix of insulin resistance and secre-
tory defects of β-cells (46).
Several options for pharmacologic therapy of lowering blood 
glucose are currently available, which have revolutionized long-
term management of DM (47). Several antidiabetic drugs may 
have important CV complications, which the provider team 
should always be aware (48). The polypharmacy issues, manage-
ment of diabetes, as well as hypertension, hyperlipidemia, and 
use of aspirin should be carefully explained to patients to ensure 
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adherence to therapy to prevent significant CV morbidity and 
mortality. Careful attention should be paid to development of 
insulinopenic states by clinical assessment of C peptide and lack 
of control of HbA1C with multiple medications, and complete 
lack of secreted insulin conditions should be treated by initiation 
of appropriate insulin regimens. Every clinical encounter should 
also be utilized to explain the benefit of weight loss and motivated 
for such. Even though not yet conclusive, clinical trial and data 
support consideration of bariatric surgery as a possible strategy 
to monitor blood glucose levels and body weight, especially in 
morbid obesity (49). Balanced hypocaloric diets that cause weight 
loss must be adopted, and regular interactions with dietitian is 
a useful approach. Aerobic training and resistance training can 
control increasing lean mass in middle-aged and overweight/
obese individuals. Behavioral strategies for weight loss should be 
encouraged in primary care settings and appropriate maintenance 
of body weight prior to conception may help after development of 
gestational diabetes. Weight loss may be particularly challenging 
for incapacitated patients and subjects with disabilities, so com-
prehensive approaches should be undertaken. Newer molecular 
studies have demonstrated the transcriptional link between 
inflammatory pathways and increased adipose tissue storage, 
contributing to insulin resistance (50). Drug repurposing of the 
anti-inflammatory agent for aphthous stomatitis, amlexanox, is 
currently undergoing trials as newer agents for management of 
diabetes (51).
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